PMC9114644_01
Pulmonary imaging by CT scan. (A) December 2015: multiple cavitary lesions and multiple patchy shadows in both the upper lungs and the dorsal segment of the left lower lung, with bronchiectases in the right middle lung and the lingual and dorsal segments of the left upper and left lower lung. (B) December 2020: multiple cystic and columnar dilated bronchial shadows of variable size in both lungs, with exudative foci in the middle lobe of the right lung. (C) 8 May 2021: diffuse multiple ground glass shadows and scattered striae in both lungs and more cystic lesions than previously observed. (D) 18 August 2021: improved infiltrations and multilobed segmental bronchiectases and bullae in both lungs.
fmed-09-835257-g0001.jpg
PMC9114644_01_fmed-09-835257-g0001.jpg
F1
The chest CT revealed multiple cavitary lesions in both upper lungs and the dorsal segment of the left lower lung and bronchiectasis of bilateral lobes (Figure 1A). The chest CT revealed bilateral multiple bronchiectases, pulmonary bulla, and atelectasis in the right middle lung lobe (Figure 1B). Pulmonary CT suggested diffuse multiple ground glass shadows and scattered striae in both lungs and more cystic lesions than previously observed (Figure 1C). The chest CT scan demonstrated improved infiltrates (Figure 1D).
Time-line with the most relevant data of the clinical case.*Salmeterol Xinafoate and Fluticasone propionate powder for inhalation. **Methylprednisolone.
fmed-09-835257-g0002.jpg
PMC9114644_01_fmed-09-835257-g0002.jpg
F2
SMZ-TMP and ganciclovir were given and symptoms were gradually relieved (Figure 2).
(A) Comparison between IgE levels during application of omalizumab and MP. (B) FEV1 and FEV1/FVC test results in different periods. (C) ACT score results in different periods.
fmed-09-835257-g0003.jpg
PMC9114644_01_fmed-09-835257-g0003.jpg
F3
The patient's symptoms and lung function improved on therapy (Figure 3).